Molecular Endocrinology, Vol 6, 920-926, Copyright © 1992 by Endocrine Society

ARTICLES

Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line

G Hayes, TJ Biden, LA Selbie and J Shine
Garvan Institute of Medical Research, Sydney, Australia.

Dopamine, a major neurotransmitter in the mammalian nervous system, exerts its physiological effects through receptors of the G-protein- coupled receptor superfamily. Two major classes of dopamine receptor, D1 and D2, are distinguishable by both biochemical and pharmacological criteria. D1 receptors activate adenylyl cyclase, whereas the D2 class of receptors inhibits this second messenger system. Two subtypes of the human dopamine D2 receptor are generated by alternate splicing of the RNA transcript of a single gene. These two forms, termed D2A (long) and D2B (short), differ by the insertion of 29 amino acids within the putative third cytoplasmic loop, an intracellular domain thought to have a role in coupling this class of receptors to particular second messenger systems. We report here that the D2A and D2B structural subtypes are also functionally distinct. Expression of the two subtypes in a fibroblast cell line revealed that while occupation of both receptors leads to an increase in cytosolic free calcium concentration, they differ in their capacity to inhibit cAMP production. At physiological dopamine concentrations, the D2B-mediated inhibition of calcitonin gene-related peptide-stimulated cAMP accumulation is almost double the response mediated by the D2A subtype. Furthermore, the D2B subtype can maximally attenuate cAMP accumulation by up to 85%, whereas the D2A subtype is less effective, maximally inhibiting cAMP accumulation by only 64%. The D2A and D2B subtypes, thus, constitute functionally distinct forms of the dopamine receptor that can couple to multiple intracellular signalling pathways.

This article has been cited by other articles:

				L. V. Neto, E. d. O. Machado, R. M. Luque, G. F. Taboada, J. B. Marcondes, L. M. C. Chimelli, L. P. Quintella, P. Niemeyer Jr., D. P. de Carvalho, R. D. Kineman, et al. Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1931 - 1937. [Abstract] [Full Text] [PDF]

				T. Gornemann, H. Hubner, P. Gmeiner, R. Horowski, K. P. Latte, M. Flieger, and H. H. Pertz Characterization of the Molecular Fragment That Is Responsible for Agonism of Pergolide at Serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A Receptors J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1136 - 1145. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				F. Gemignani, S. Landi, V. Moreno, L. Gioia-Patricola, A. Chabrier, E. Guino, M. Navarro, M. Cambray, G. Capella, F. Canzian, et al. Polymorphisms of the Dopamine Receptor Gene DRD2 and Colorectal Cancer Risk Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1633 - 1638. [Abstract] [Full Text] [PDF]

				R. Pivonello, D. Ferone, W. W. de Herder, R. R. de Krijger, M. Waaijers, D. M. Mooij, P. M. van Koetsveld, A. Barreca, M. L. Del Basso De Caro, G. Lombardi, et al. Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4493 - 4502. [Abstract] [Full Text] [PDF]

				R. Pivonello, C. Matrone, M. Filippella, L. M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, and G. Lombardi Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1674 - 1683. [Abstract] [Full Text] [PDF]

				S. Glaser, D. Alvaro, T. Roskams, J. L. Phinizy, G. Stoica, H. Francis, Y. Ueno, B. Barbaro, M. Marzioni, J. Mauldin, et al. Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-gamma expression and decrease of PKA activity Am J Physiol Gastrointest Liver Physiol, April 1, 2003; 284(4): G683 - G694. [Abstract] [Full Text] [PDF]

				P. J. Pauwels, F. Finana, S. Tardif, T. Wurch, and F. C. Colpaert Dynamic Dopamine-Antagonist Interactions at Recombinant Human Dopamine D2short Receptor: Dopamine-Bound versus Antagonist-Bound Receptor States J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 133 - 140. [Abstract] [Full Text]

				M. H. Ghahremani, P. Cheng, P. M. C. Lembo, and P. R. Albert Distinct Roles for Galpha i2, Galpha i3, and Gbeta gamma in Modulation of Forskolin- or Gs-mediated cAMP Accumulation and Calcium Mobilization by Dopamine D2S Receptors J. Biol. Chem., April 2, 1999; 274(14): 9238 - 9245. [Abstract] [Full Text] [PDF]

				D. Lee, P. Dong, D. Copolov, and A. T. Lim D5 Dopamine Receptors Mediate Estrogen-Induced Stimulation of Hypothalamic Atrial Natriuretic Factor Neurons Mol. Endocrinol., February 1, 1999; 13(2): 344 - 352. [Abstract] [Full Text]

				U. Renner, T. Arzberger, U. Pagotto, S. Leimgruber, E. Uhl, A. Müller, M. Lange, A. Weindl, and G. K. Stalla Heterogenous Dopamine D2 Receptor Subtype Messenger Ribonucleic Acid Expression in Clinically Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1368 - 1375. [Abstract] [Full Text]

				A. M. Lew and H. P. Elsholtz A Dopamine-responsive Domain in the N-terminal Sequence of Pit-1 J. Biol. Chem., March 31, 1995; 270(13): 7156 - 7160. [Abstract] [Full Text] [PDF]